Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02727127 · ClinicalTrials.gov registry record
Brain Ion Homeostasis, Lithium and Bipolar Disorder
A clinical trial, sponsored by NYU Langone Health.
- Terminated
- Registry status
- 26
- Enrollment target
NCT02727127: Clinical Trial study, sponsored by NYU Langone Health.
NCT02727127 is a clinical trial that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02727127 was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- 26 participants
- Enrollment target
Study Summary
In this project, investigators intend to carry out the first simultaneous, in vivo, imaging study of lithium content and sodium ion homeostasis in the brain of Bipolar Disorder (BPD) patients under Lithium therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-09-11 |
Why NCT02727127 stopped before completion
NCT02727127 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02727127 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02727127 about?
NCT02727127 is a clinical study titled "Brain Ion Homeostasis, Lithium and Bipolar Disorder". In this project, investigators intend to carry out the first simultaneous, in vivo, imaging study of lithium content and sodium ion homeostasis in the brain of Bipolar Disorder (BPD) patients under Lithium therapy.
What is the current status of trial NCT02727127?
This trial is currently terminated. The enrollment target is 26 participants. The study started on 2015-09. Estimated completion is 2019-09-11.
Who is sponsoring clinical trial NCT02727127?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia